6.92 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||6.90 x 900|
|Ask||6.93 x 1000|
|Day's Range||6.64 - 6.95|
|52 Week Range||4.42 - 9.75|
|Beta (3Y Monthly)||2.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
“The novel data presented at AACR provide mechanistic insights into the biological activity of our microbiome therapeutic candidates to augment immune checkpoint inhibitors,” said Matthew Henn, Ph.D., Chief Scientific Officer and Executive Vice President at Seres. Seres presented preclinical results evaluating the impact of various consortia of bacterial species on the anti-tumor immune response in murine models following treatment with an anti-PD-1 checkpoint inhibitor.
Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person’s gut could help fight cancer.
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer –
- Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis -
Seres Therapeutics, Inc. today announced that it will present at each of the following upcoming healthcare conferences:
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
“We believe that microbiome therapeutics have an important role in the future of medicine for a range of serious diseases and that Seres is well positioned to drive progress in the field with our late-stage clinical-stage programs, differentiated drug discovery and state-of-the-art manufacturing capabilities. Following a comprehensive review of our pipeline, we are concentrating our resources on obtaining clinical results from our highest-priority, late-stage clinical programs in ulcerative colitis and C. difficile infection as well as our soon-to-be initiated Phase 1b study in patients with metastatic melanoma,” said Eric Shaff, President and Chief Executive Officer of Seres Therapeutics.
Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff has also joined Seres’ Board of Directors and will continue to serve as Seres’ principal financial officer on an interim basis. Dr. Pomerantz will continue as Chairman of Seres’ Board of Directors.
Roger Pomerantz has been the CEO of Seres Therapeutics, Inc. (NASDAQ:MCRB) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
“Advancing SER-287 into a late stage Phase 2B trial is a significant achievement,” said Kevin Horgan, M.D., Executive Vice President and Chief Medical Officer. “We are hopeful that SER-287 may provide individuals with ulcerative colitis with a novel microbiome-based, non-immunosuppressive therapy that addresses the underlying pathology of this serious disease. The SER-287 Phase 2B ECO-RESET study has been designed as a pivotal trial.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Seres Therapeutics, Inc. today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET.
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 5.26% and -61.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer -
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.
Dr. Horgan will lead Seres’ clinical development, clinical operations, regulatory affairs, and medical affairs functions. Dr. Horgan will succeed Seres’ outgoing Chief Medical Officer, Michele Trucksis, Ph.D., M.D., who will continue to provide consulting services to the Company.
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection